徐林,金立军,何晓玲,魏涵

• 1:长江大学临床医学院
• 2:长江大学附属第一医院心血管内科

摘要(Abstract)：

<正>自1997年以来,氯吡格雷联合阿司匹林成为治疗急性冠状动脉综合征(acute coronary syndrome,ACS)的基石,得到国内外临床指南的I级推荐~([1-3])。但是,越来越多的研究表明,接受规范化治疗的部分ACS患者出现"阿司匹林抵抗"和"氯吡格雷抵抗"等反应,体现了氯吡格雷联合阿司匹林治疗ACS的局限性~([4])。PIATO研究~([5])显示,与氯吡格雷相比,替格瑞洛显著降低ACS患者包括心血管死亡、心肌梗死和卒中在内的主要复合终点事件的发生率,且并未显著增加

关键词(KeyWords)： 替格瑞洛;腺苷;腺苷三磷酸;生物学效应

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 徐林,金立军,何晓玲,魏涵

参考文献(References)：

• [1]Ari H,Ozkan H,Karacinar A,et al.The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance(The EFFICIENT Trial).Int J Cardiol,2012,157:374-380.
• [2]张斌.2013ACCF/AHAST段抬高心肌梗死治疗指南解读.中国介入心脏病学杂志,2014,22:608-610.
• [3]郭新贵.解读欧美指南-再议新型P2Y_(12)抑制剂治疗地位.中国介入心脏病学杂志,2015,23:55-58.
• [4]Gurbel PA,Bliden KP,Butler K,et al.Response to ticagrelor in clopidogrel nonrcspondcrs and responders and effect of switching therapies;the RESPOND study.Circulation,2010,121:1188-1199.
• [5]Wallentin L,James S,Storey RF,et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial.Lancet,2010,376;1320-1328.
• [6]Bonello L,Laine M,Kipson N,et al.Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome.J Am Coll Cardiol,2014,63:872-877.
• [7]Cattaneo M.The platelet P2Y12 receptor for adenosine diphosphate congenitaland;drug-induced defects.Blood,2011,117:2102-2112.
• [8]Cattaneo M,Schulz R,Nylander S.Adenosinemediated effects of ticagrelor;evidence and potential clinical relevance.J Am Coll Cardiol,2014,63:2503-2509.
• [9]Cattaneo M,Faioni EM.Why does ticagrelor induce dyspnea?Thromb Haemost,2012,108:1031-1036.
• [10]Schneider DJ.Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy.J Am Coll Cardiol,2011,57;685-687.
• [11]Bertrand ME,Rupprecht HJ,Urban P,et al.Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:the clopidogrel aspirin stmt international cooperative study(CLASSICS).Circulation,2000,102:624-629.
• [12]Li H,Butler K.Yang L,et al.Pharmacokinetics and tolerability of single and multiple doses of ticagrclor in healthy Chinese subjects;an open-label,sequential,two-cohort,single-centre study.Clin Drug Investig,2012,32:87-97.
• [13]Hasko G,Cronstein B.Regulation of inflammation by adenosine.Front Immunol,2013,4:85.
• [14]Mustafa SJ,Morrison RR,Teng B,et al.Adenosine receptors and the heart;role in regulation of coronary blood flow and cardiac electrophysiology.Handb Exp Pharmacol,2009,193:161-188.
• [15]Talukder MA,Morrison RR,Jacobson MA,et al.Targeted deletion of adenosine A(3)receptors augments adenosineinduced coronary flow in isolated mouse heart.Am J Physiol Heart Circ Physiol,2002,282:H2183-H2189.
• [16]Johnston-Cox HA,Yang D,Ravid K.Physiological implications of adenosine receptor-mediated platelet aggregation.J Cell Physiol,2011,226:46-51.
• [17]Csoka B,Nemeth ZH,Rosenberger P,et al.A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation.J Immunol,2010,185:542-550.
• [18]Belardinelli L,Shryock JC,Song Y,et al.Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes.FASEB J,1995,9:359-365.
• [19]Gerczuk PZ.Kloner RA.An update on cardioprotection:a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials.J Am Coll Cardiol,2012,59:969-978.
• [20]Headrick JP,Lasley RD.Adenosine receptors and reperfusion injury of the heart.Handb Exp Pharmacol,2009,193:189-214.
• [21]Garcia-Dorado D,Otaegui I,Rodriguez Palomares JF,et al.Primary results of the PROMISE trial:myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI.Eur Heart J.2013,34(Issue suppl 1):669.
• [22]Rose JB,Naydenova Z,Bang A,et al.Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection.Am J Physiol Heart Circ Physiol,2010,298:H771-H777.
• [23]Gregorini L,Marco J,Farrah B,et al.Effects of adenosine and alphal-adrenergic blockers on the no-reflow phenomenon.J Am Coll Cardiol,2001,37(Suppl A):1094-1177.
• [24]Gonzalez-Alonso J,Olsen DB,Saltin B.Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery:role of circulating ATP.Circ Res,2002,91:1045-1055.
• [25]JOhman J,Kudira R,Albinsson S,et al.Ticagrelor induces adenosine triphosphate release from human red blood cells.Biochem Biophys Res Commun,2012,418:754-758.
• [26]Sridharan M,Adderley SP,Bowles E A,et al.Pannexin 1 is the conduit for low oxygen tension-induced ATP release from human erythrocytes.Am J Physiol Heart Circ Physiol,299:H1146-H1152.
• [27]Gonzalez-Alonso J,Olsen DB,Saltin B.Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery:role of circulating ATP.Circ Res,91;1046-1055.
• [28]Nylander S,Femia EA,Scavone M,et al.Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12antagonism.J Thromb Haemost,2013,11:1867-1876.
• [29]Armstrong D,Summers C,Ewart L,et al.Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.J Cardiovasc Pharmacol Ther,2014,19:209-219.
• [30]Moser GH,Schrader J,Deussen A.Turnover of adenosine in plasma of human and dog blood.Am J Physiol,1989,256:C799-C806.
• [31]Bonello L,Laine M,Kipson N,et al.Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.J Am Coll Cardiol,2014,63:872-877.
• [32]van Giezen JJ,Sidaway J,Glaves P,et al.Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.J Cardiovasc Pharmacol Ther,2012,17:164-172.
• [33]Wittfeldt A,Emanuelsson H,Brandrup-Wognsen G,et al.Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.J Am Coll Cardiol,2013,61;723-727.
• [34]颜红兵,邵春丽,霍勇.要重视替格瑞洛相关的呼吸困难.中国介入心脏学杂志,2015,23:2-4.
• [35]Torngren K,Ohman J,Salmi H,et al.Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.Cardiology,2013,124:252-258.
• [36]Storey RF,James SK,Siegbahn A,et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.Platelets,2014,25:517-525.
• [37]Zaza A,Rocchetti M,DiFrancesco D.Modulation of the hyperpolarization-activated current(I(f))by adenosine in rabbit sinoatrial myocytes.Circulation,1996,94:734-741.